JavaScript seems to be disabled in your browser. You must have JavaScript enabled in your browser to utilize the functionality of this website.
Description: PD1-PDL1 inhibitor 2 (also known as BMS-202, BMS 202, BMS202), is a novel and potent inhibitor of the PD-1 (Programmed death- 1)/PD-Ll (Programmed death-ligand 1) protein/protein interaction with potential antineoplastic activity. It was reported in patent WO/2015034820 A1, compound example 202. Homogenous time-resolved fluorescence (HTRF) assay showed that BMS-202 has good in vitro activity with IC50 values of less than 50 nM in the cell-free assay. However, no in vivo data has been reported for this compound. Structural basis for blocking the PD-1/PD-L1 interaction by small molecule BMS-202 that binds to and induces dimerization of PD-L1.
References: J Med Chem. 2017 Jul 13; 60(13):5857-5867; WO/2015034820 A1
Publications Citing Use of InvivoChem BMS-202:
1) J Med Chem. 2020 Dec 24; 63(24):15946-15959. doi: 10.1021/acs.jmedchem.0c01684;
2) J Med Chem. 2020 Aug 13; 63(15):8338-8358. doi: 10.1021/acs.jmedchem.0c00574.
Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.
All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.
Request Data Sheet
Request product datasheet
Request safety datasheet
Compare
Add to wishlist
Get an offer
Request delivery time
Ask a technical question
Submit a bulk request
sales@hoelzel.de
« Back
Subscribe, get 15% off every fifth order and have your items delivered on time!
Forgot Your Password?
Not yet registered? Create account here!